NDA 020819 · Abbvie
Zemplar
Paricalcitol · Intravenous · Vitamin D2 Analog; Vitamin D Analog
NovelOrphanLast checked: Nov 20, 2026Latest source record: Oct 20, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Apr 17, 1998
Approved uses
3
Original approval plus efficacy supplements
Registered trials
101
23 Phase 3, 1 recruiting
FAERS reports
14,054
12,725 serious, 8,430 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 1, 2024.
ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. ZEMPLAR is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis ( 1 ).
Mechanism: Paricalcitol is a synthetic, biologically active vitamin D 2 analog. Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce PTH levels by inhibiting PTH synthesis and secretion.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 31, 2004 Supplement 14 · Efficacy · priority review LabelLetter
- Feb 2, 2000 Supplement 3 · Efficacy LetterLabel
- Apr 17, 1998 Original approval · Type 1 - New Molecular Entity LabelPediatric Written RequestPediatric Reissue Amendment 1
3 products under this application
- ZEMPLAR · PARICALCITOL 0.01MG/2ML (0.005MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- ZEMPLAR · PARICALCITOL 0.005MG/ML (0.005MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- ZEMPLAR · PARICALCITOL 0.002MG/ML (0.002MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Paricalcitol" as an intervention, any sponsor and status, largest first.
- Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on HemodialysisPivotal-lookingTerminated
AbbottIndustry
NCT00062699 · 2,200 participants · Start Apr 2003
Drug: Zemplar (paricalcitol injection); Calcijex · For: End-Stage Kidney Disease
Sites: Tuscaloosa, Alabama; Inglewood, California; Los Angeles, California · 60 sites in all
- Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing HemodialysisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01181531 · 312 participants · Start Oct 1, 2010 · Primary completion Jul 17, 2012
Drug: Traditional Vitamin D Therapy; Cinacalcet · For: Hyperparathyroidism, Secondary
- Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002Pivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT02282813 · 298 participants · Start Apr 2013 · Primary completion May 2015
Drug: CTAP101 Capsules; Calcitriol and 2 more · For: Chronic Kidney Disease; Hyperparathyroidism, Secondary; Vitamin D Deficiency
- The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System InhibitorsPivotal-lookingCompleted
AbbottIndustry
NCT00421733 · 281 participants · Start Dec 2006 · Primary completion Jun 2009
Drug: Zemplar (paricalcitol ) capsules; Zemplar (paricalcitol) capsules and 1 more · For: Diabetic Nephropathy; Chronic Kidney Disease
Sites: Phoenix, Arizona; Fountain Valley, California; Yuba City, California · 72 sites in all
- Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin DPivotal-lookingCompleted
AbbottIndustry
NCT00977080 · 272 participants · Start Nov 2009 · Primary completion May 2011
Drug: Paricalcitol; Cinacalcet · For: Chronic Kidney Disease; Secondary Hyperparathyroidism; Hemodialysis
Sites: Tempe, Arizona; Chula Vista, California; Los Angeles, California · 83 sites in all
- Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismPivotal-lookingCompleted
AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
NCT01341782 · 255 participants · Start May 2011 · Primary completion Apr 2012
Drug: paricalcitol; maxacalcitol and 2 more · For: Secondary Hyperparathyroidism; Hemodialysis
Sites: Aichi, Japan; Chiba, Japan; Gifu, Japan · 45 sites in all
- The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4Pivotal-lookingCompleted
AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
NCT00497146 · 227 participants · Start Feb 2008 · Primary completion Sep 2010
Drug: paricalcitol; placebo · For: Chronic Kidney Disease; Left Ventricular Hypertrophy
Sites: Phoenix, Arizona; Tempe, Arizona; San Diego, California · 71 sites in all
- Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney DiseasePivotal-lookingCompleted
AbbottIndustry
NCT01071070 · 216 participants · Start Nov 2009 · Primary completion Nov 2010
Drug: paricalcitol · For: Chronic Kidney Disease
Sites: Beijing, China; Dalian, China; Guangzhou, China · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death3,570
- cardiac disorder622
- myocardial infarction584
- sepsis483
- cardio-respiratory arrest477
- dyspnoea395
- cardiac failure348
- renal failure308
- pneumonia303
- nausea302
- cerebrovascular accident285
- asthenia277
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 71 |
| 2006 | 148 |
| 2007 | 159 |
| 2008 | 335 |
| 2009 | 705 |
| 2010 | 449 |
| 2011 | 499 |
| 2012 | 368 |
| 2013 | 1,819 |
| 2014 | 2,367 |
| 2015 | 2,117 |
| 2016 | 1,826 |
| 2017 | 797 |
| 2018 | 628 |
| 2019 | 515 |
| 2020 | 377 |
| 2021 | 268 |
| 2022 | 246 |
| 2023 | 212 |
| 2024 | 60 |
| 2025 | 31 |
| 2026 | 29 |
Recalls
1 FDA enforcement reports for this application.
May 14, 2012 · Class II · Terminated
CGMP Deviations: There is potential that Abbott's third party manufacturer, Hospira, may have applied a foreign (incorrect) stopper to vials in a specific lot of Zemplar Injection.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zemplar* (Paricalcitol)
2024 spending
$20K
Beneficiaries
11
32 claims
Per beneficiary
$1,831
$12.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $38,403 |
| 2021 | $18,413 |
| 2022 | $23,926 |
| 2023 | $19,438 |
| 2024 | $20,136 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.
Chung V, Alistar A, Becerra C, et al. · Oncologist 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
- Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.
Perez KJ, Dias Costa A, Jordan A, et al. · Nat Cancer 2026 · Randomized Controlled Trial
- Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
Martin KJ, González EA, Gellens ME, et al. · Am J Kidney Dis 1998 · Clinical Trial, Multicenter Study
- The role of paricalcitol on proteinuria.
Aperis G, Paliouras C, Zervos A, et al. · J Ren Care 2011 · Clinical Trial
- Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis.
Liu X, Liu Y, Zheng P, et al. · Eur J Clin Pharmacol 2024 · Network Meta-Analysis
- The effect of oral supplementation of Paricalcitol on C-reactive protein levels in chronic kidney disease patients: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials.
Arabi SM, Shahraki-Jazinaki M, Chambari M, et al. · BMC Pharmacol Toxicol 2024 · Meta-Analysis, Systematic Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.